Abstract
Elizabeth S. Waxman, RN, MSN, AOCN®, ANP-BC, of MD Anderson Cancer Center, reviews research in thoracic cancers presented at the 2022 ASCO Annual Meeting, including neoadjuvant immunotherapy for resectable stage IIIA non–small cell lung cancer, a new drug inhibiting KRAS G12C, and options after disease progression on immune checkpoint inhibitor treatment or targeted treatment.
